Nkarta reports FY2023 net loss $117.5M; deprioritizes NKX101, advances NKX019 in autoimmune

Nkarta, Inc.

FY2023 net loss of $117.5M ($2.40 per basic/diluted share).
Year-end cash, equivalents & investments $250.9M; expected to fund operations into 2026.
NKX019 lupus nephritis trial on track to dose first patient in H1 2024.
NKX101 AML program deprioritized after CR/CRi rate 5/20 vs 4/6 in first 6 patients.
NKX019 compressed dosing cohort in NHL; preliminary data expected mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nkarta, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-034710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.